English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Cannabinoid-based medicines for the treatment of Gilles de la Tourette syndrome

Kanaan, A. S., & Müller-Vahl, K. (2017). Cannabinoid-based medicines for the treatment of Gilles de la Tourette syndrome. In V. Preedy (Ed.), Handbook of cannabis and related pathologies: Biology, pharmacology, diagnosis, and treatment (pp. 883-892). Academic Press.

Item is

Basic

show hide
Item Permalink: http://hdl.handle.net/11858/00-001M-0000-002B-1B12-9 Version Permalink: http://hdl.handle.net/21.11116/0000-0004-D947-8
Genre: Book Chapter

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Kanaan, Ahmad S.1, 2, Author              
Müller-Vahl, Kirsten 2, Author
Affiliations:
1Methods and Development Unit Nuclear Magnetic Resonance, MPI for Human Cognitive and Brain Sciences, Max Planck Society, ou_634558              
2Department of Psychiatry, Social psychiatry and Psychotherapy, Hannover Medical School MHH, Germany, ou_persistent22              

Content

show
hide
Free keywords: Tourette syndrome ; tics ; cannabinoids ; Cannabis sativa ; Δ9-tetrahydrocannabinol ; THC ; ADHD ; attention deficit/hyperactivity disorder ; OCD ; obsessive-compulsive disorder
 Abstract: Gilles de la Tourette syndrome (GTS) is a common psychiatric movement disorder that is characterized by motor and vocal tics and a strong association with comorbid obsessive compulsive disorder (OCD) and attention deficit/hyperactivity disorder (ADHD). On a systems level, the primary abnormality has been shown to be related to dopaminergic neurotransmission within cortico-striato-thalamo-cortical (CSTC) circuits, though a complete picture of the disorder’s pathophysiology remains elusive. Clinically, the therapeutic spectrum for GTS has been expanding over the last decade, though current treatment strategies are often ineffective and unsatisfactory. As a result, there is an urgent need for uncovering novel treatment strategies that could ameliorate both motor and behavioral symptoms, are more effective in treatment resistant patients, and cause less adverse effects. Early anecdotal reports have provided evidence that patients with GTS choose cannabinoids as a form of self-medication. As a result, several groups began investigating the role of the endocannabinoid system in GTS pathophysiology and cannabinoid based medicines as a form of treatment. Currently, there are a limited number of studies suggesting that oral Δ9-tetrahydrocannabinol (THC) is effective in the treatment of tics and behavioral comorbidities. Consequently, the role of the endocannabinoid system in GTS pathophysiology remains speculative, as further investigation on the role of the endocannabinoid system in GTS is needed. In this chapter, we review the state of the art and highlight studies that explored the role of the endocannabinoid system and cannabinoids based medicine in GTS.

Details

show
hide
Language(s): eng - English
 Dates: 2016-05-182017-01-01
 Publication Status: Published in print
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Method: -
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Handbook of cannabis and related pathologies: Biology, pharmacology, diagnosis, and treatment
Source Genre: Book
 Creator(s):
Preedy, Victor, Editor
Affiliations:
-
Publ. Info: Academic Press
Pages: 1170 Volume / Issue: - Sequence Number: - Start / End Page: 883 - 892 Identifier: ISBN: 978-0-12-800756-3
DOI: 10.1016/C2013-0-18721-1